The Supreme Court on May 14 granted an indefinite stay of a Fifth Circuit order that would have reinstated in-person dispensing requirements for…
The Supreme Court on May 14 granted an indefinite stay of a Fifth Circuit order that would have reinstated in-person dispensing requirements for mifepristone nationwide, preserving telehealth prescribing and mail delivery of the abortion pill while underlying litigation continues [1]. The stay blocks restrictions that would have ended the current regulatory framework allowing patients to obtain mifepristone without an in-person clinical visit [2]. Justices Samuel Alito and Clarence Thomas dissented, with Thomas invoking the Comstock Act as a potential basis for restricting mail distribution of the drug and Alito arguing the majority was undermining the Court's 2022 decision in *Dobbs v. Jackson Women's Health Organization* [1].
The case, *Louisiana v. FDA*, is a challenge by Louisiana Attorney General Liz Murrill to the Food and Drug Administration's regulatory framework governing mifepristone access [3]. The Fifth Circuit had ruled in Louisiana's favor, which would have triggered the in-person dispensing mandate pending appeal. Mifepristone manufacturers Danco Laboratories and GenBioPro filed the emergency applications seeking relief from the Supreme Court after the FDA declined to submit its own briefs defending the agency's approvals [1][2]. The case is now pending before the Fifth Circuit on the merits.
The ruling carries immediate nationwide effect. The FDA's current dispensing rules, which allow certified pharmacies and telehealth providers to dispense mifepristone by mail, remain operative in all states where the drug is legal [3]. The practical consequence is that patients in states without abortion bans retain access under conditions that have been in place since the FDA loosened its Risk Evaluation and Mitigation Strategy requirements in 2021 and expanded them in 2023. The FDA's posture of non-participation, leaving private manufacturers to defend agency policy before the nation's highest court, is itself a notable departure from standard executive-branch litigation practice [1].
The dissents foreshadow a broader doctrinal contest. Thomas's citation of the Comstock Act, an 1873 law prohibiting mailing of obscene materials that some legal advocates argue covers abortion drugs, signals that at least two justices view the statute as a live legal theory [1]. That argument has not yet commanded a majority but is being litigated in parallel proceedings. The Fifth Circuit will now proceed to a full merits review of the FDA's authority to loosen mifepristone's dispensing conditions, setting up a likely return to the Supreme Court on the question of whether the agency acted within its statutory authority under the Food, Drug, and Cosmetic Act [2][3].
—
**Meta Description:** The Supreme Court indefinitely blocked a Fifth Circuit order that would have required in-person mifepristone dispensing, preserving telehealth access as litigation continues.
**Slug:** supreme-court-stays-mifepristone-fifth-circuit-order
**Tags:** Legal News, Motion Ruling, Louisiana v. FDA, United States, Washington DC, Abortion Access, FDA Authority, Comstock Act, U.S. Supreme Court, Danco Laboratories, GenBioPro, Samuel Alito, Clarence Thomas, Administrative Law, Emergency Docket
**Metadata:**
– subject: Louisiana v. FDA / Mifepristone Telehealth Access
– subject_type: Motion Ruling
– date: 2026-05-14
– jurisdiction: federal
– country: US
– region: N/A
– city: Washington
– key_people: Samuel Alito, Clarence Thomas, Liz Murrill
– key_organizations: U.S. Supreme Court, Danco Laboratories, GenBioPro, FDA, Planned Parenthood
– themes: Abortion Access, FDA Authority, Comstock Act
– significance: The Court's indefinite stay is the most consequential federal abortion-access ruling since Dobbs, preserves a nationwide telehealth dispensing framework, and places Comstock Act arguments within striking distance of a majority opinion.
**References:**
[1] NPR. (2026, May 14). The Supreme Court keeps abortion pill mifepristone available by telehealth. https://www.npr.org/2026/05/14/nx-s1-5821591/mifepristone-supreme-court-louisiana-telehealth
[2] Axios. (2026, May 14). Supreme Court allows abortion pill access while lawsuit proceeds. https://www.axios.com/2026/05/14/supreme-court-abortion-pill-mifepristone-mail-freeze-ruling
[3] CNBC. (2026, May 14). Supreme Court allows mail-order of abortion pill mifepristone pending appeal. https://www.cnbc.com/2026/05/14/supreme-court-abortion-mifepristone-mail-order-appeal.html